Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · HCG

HCG

HealthcareHealthcare Services₹8931 cr market cap
₹614.05 ▲ +2.45% today As of 19 Nov 2026
52-week low ₹521.7552-week high ₹746.83

-19.7% from the 52-week high · +14.9% above the low

HealthCare Global Enterprises Ltd. provides imaging and diagnostics services for cancer treatment. The company is headquartered in Bangalore, Karnataka and currently employs 5,679 full-time employees. The company went IPO on 2016-03-30. The firm is involved retail sale of pharmaceuticals, medical and orthopedic goods and toilet articles. The company operates cancer care network under the HCG brand. The company operates infertility treatment clinics providing assisted reproductive services under brand Milann. The firm operates eight Milann fertility centers, which provide reproductive medicine services, including assisted reproduction, gynecological endoscopy and fertility preservation; and follow a multidisciplinary and technology-focused approach to diagnosis and treatment. Milann fertility centers also offer training programs for fertility specialists and embryologists. Under the Triesta brand, it provides clinical reference laboratory services with specialization in oncology.

The short version. HCG reported revenue of ₹732 crore for Sep 2026, up 13.1% from a year earlier. Net profit was ₹5 crore (down 68.8% year on year). Return on equity was 1.0% in Mar 2026. Promoter holding was 64.21% in Sep 2026, down 7.01 points over 8 quarters.

1 · The price

How has the stock traded?

HCG trades 19.7% below its 52-week high and 14.9% above its 52-week low.

Change over period: —

1M+5.2%
3M-19.6%
6M-8.1%
1Y-18.1%

2 · The business

Is it growing?

Sales, year on year+13.1%

Sep 2026 revenue of ₹732 cr.

Profit, year on year-68.8%

Sep 2026 net profit of ₹5 cr.

Net margin0.7%

1.8 pts lower than a year earlier.

3-year growth-22.3% profit

Revenue compounded at 14.6% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue732695652633647613585558
Net profit5142-916577
Net margin %0.72.00.3-1.52.50.81.31.3
EPS (₹)0.320.920.15-0.631.090.320.50.47

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue2545222319121694139810131096976
Net profit1444482954-193-107-25
Net margin %0.52.02.51.73.8-19.1-9.7-2.5
EPS (₹)0.923.013.261.993.65-14.58-11.36-2.66

3 · The quality

How well does it turn capital into profit?

Return on equity was 1.0% in Mar 2026; debt to equity is 0.68.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %1.04.85.83.4
Return on capital %6.98.49.08.5
EBITDA margin %17.418.718.218.3
Net margin %0.52.02.51.7

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR14.6%20.1%
Profit CAGR-22.3%—
Debt to equity0.68
Interest cover1.1x
Current ratio1.09

4 · The owners

Who holds it, and are they adding?

Promoter holding64.21%

Down 7.01 pts over 8 quarters.

Foreign institutions2.69%

Down 0.08 pts over 8 quarters.

Domestic institutions20.77%

Up 7.83 pts over 8 quarters.

Mutual fund schemes41

+4 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter71.2271.2262.4663.7863.7764.2164.2164.21-7.01
FII2.772.452.163.593.222.752.742.69-0.08
DII12.9412.4713.2218.3618.318.9119.220.77+7.83
Public13.0613.8622.1614.2714.7114.1313.8512.32-0.74

Mutual fund holdings · Oct 2026

41 schemes hold this stock

37 the month before.

  • TATA INDIA PHARMA & HEALTHCARE FUND5.25% of NAV
  • Motilal Oswal Consumption Fund3.76% of NAV
  • TATA FOCUSED FUND3.7% of NAV
  • Nippon India ELSS Tax Saver Fund1.56% of NAV
  • TATA AGGRESSIVE HYBRID FUND1.47% of NAV
  • Groww BSE Hospitals ETF1.41% of NAV
  • SBI Healthcare Opportunities Fund1.35% of NAV
  • TATA CHILDRENS FUND1.2% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for HCG are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about HCG

What is the HCG share price?

HCG (HCG) last closed at ₹614.05, up 2.45% on the day. Its 52-week range is ₹521.75 to ₹746.83.

What is the market cap of HCG?

HCG has a market capitalisation of about ₹8,931 crore.

How are HCG's latest results?

HCG reported revenue of ₹732 crore for Sep 2026, up 13.1% from a year earlier. Net profit was ₹5 crore (down 68.8% year on year). Return on equity was 1.0% in Mar 2026. Promoter holding was 64.21% in Sep 2026, down 7.01 points over 8 quarters.

Who owns HCG?

As of Sep 2026, shareholding was: Promoter 64.21%, FII 2.69%, DII 20.77%, Public 12.32%.

How many mutual funds hold HCG?

41 mutual fund schemes held HCG in October 2026. That compares with 37 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 02 Mar 2026 · Rights issue 1:17

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.